Golden State Wealth Management LLC Has $1.80 Million Stake in Johnson & Johnson (NYSE:JNJ)

Golden State Wealth Management LLC raised its holdings in Johnson & Johnson (NYSE:JNJ - Free Report) by 157.8% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 10,835 shares of the company's stock after purchasing an additional 6,632 shares during the quarter. Golden State Wealth Management LLC's holdings in Johnson & Johnson were worth $1,798,000 as of its most recent SEC filing.

Several other institutional investors have also recently bought and sold shares of JNJ. Norges Bank bought a new position in Johnson & Johnson in the 4th quarter valued at $4,390,037,000. Raymond James Financial Inc. bought a new position in Johnson & Johnson in the 4th quarter valued at $1,339,878,000. GAMMA Investing LLC raised its position in Johnson & Johnson by 24,450.4% in the 1st quarter. GAMMA Investing LLC now owns 7,215,367 shares of the company's stock valued at $1,196,596,000 after purchasing an additional 7,185,977 shares during the last quarter. Janus Henderson Group PLC raised its position in Johnson & Johnson by 134.5% in the 4th quarter. Janus Henderson Group PLC now owns 7,948,508 shares of the company's stock valued at $1,149,536,000 after purchasing an additional 4,559,147 shares during the last quarter. Finally, Northern Trust Corp raised its position in Johnson & Johnson by 12.3% in the 4th quarter. Northern Trust Corp now owns 30,813,175 shares of the company's stock valued at $4,456,201,000 after purchasing an additional 3,363,235 shares during the last quarter. Institutional investors own 69.55% of the company's stock.

Johnson & Johnson Stock Down 0.0%

NYSE:JNJ opened at $152.25 on Friday. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $169.99. The company has a current ratio of 1.26, a quick ratio of 1.03 and a debt-to-equity ratio of 0.49. The stock has a market cap of $366.33 billion, a price-to-earnings ratio of 16.94, a PEG ratio of 2.31 and a beta of 0.42. The stock has a 50-day moving average price of $153.85 and a two-hundred day moving average price of $153.69.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its earnings results on Tuesday, April 15th. The company reported $2.77 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.59 by $0.18. Johnson & Johnson had a return on equity of 33.46% and a net margin of 24.42%. The firm had revenue of $21.89 billion during the quarter, compared to analysts' expectations of $21.65 billion. As a group, equities analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, June 10th. Stockholders of record on Tuesday, May 27th were given a dividend of $1.30 per share. This is a boost from Johnson & Johnson's previous quarterly dividend of $1.24. This represents a $5.20 annualized dividend and a dividend yield of 3.42%. The ex-dividend date was Tuesday, May 27th. Johnson & Johnson's dividend payout ratio is currently 57.84%.

Wall Street Analyst Weigh In

A number of research analysts have commented on JNJ shares. Guggenheim reiterated a "neutral" rating on shares of Johnson & Johnson in a research report on Wednesday, April 2nd. Royal Bank Of Canada reiterated an "outperform" rating and issued a $181.00 price objective on shares of Johnson & Johnson in a research report on Thursday, June 5th. Wall Street Zen upgraded Johnson & Johnson from a "buy" rating to a "strong-buy" rating in a research report on Saturday, June 21st. Leerink Partners lowered Johnson & Johnson from an "outperform" rating to a "market perform" rating and decreased their price objective for the company from $169.00 to $153.00 in a research report on Tuesday, May 13th. Finally, The Goldman Sachs Group upgraded Johnson & Johnson from a "neutral" rating to a "buy" rating and increased their price objective for the company from $157.00 to $172.00 in a research report on Wednesday, April 9th. Eleven research analysts have rated the stock with a hold rating, seven have given a buy rating and three have assigned a strong buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $170.88.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.